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The classical sulphonylurea derivative glibenclamide interaction with K AT1)-channel-opening drugs, glib-
is widely prescribed for the trea tm ent of non-insulin- enclamide has also been reported  to inhibit the va-
dependent diabetes mellitus (N ID D M ). The m echa- sodilator response to adenosine, and to (endothe-
nism of action of this drug is based on an augm ented lium -dependent) vasodilators such as acetylcholine,
release of insulin from  the beta  cells of the  pancreas, vasoactive intestinal peptide and insulin [4], Also in
triggered by the  closing of so-called A T P-dependent the myocardial cell, glibenclam ide is able to reduce
potassium  channels (ATP: adenosine’5-triphosphate) the response to K AT1,-channel-opening agents [4],
['11. This ultim ately results in an influx of calcium via Animal experim ents have shown that the ischae-
opening of voltage-dependent calcium-ion channels, m ia-induced opening of m yocardial KAn.-ehannels is
and the subsequent binding of calcium ions to  cal- an endogenous cardioprotective m echanism  against
m odulin triggers the exocytosis of insulin-containing ischaemia and reperlusion dam age. In several ischae-
secretory granules. The central issue of this presenta- mia models glibenclamide increased infarct size [5 ,6],
tion is the fact that the occurrence of K ATP-channels On the other hand blockade of the su lphonylurea re-
is not restricted  to the pancreatic be ta  cells. These ceptor is associated with a reduction in ischaem ia-re-
particular ion channels occur in several organ sys- lated arrhythm ias [4]. N ot only m yocardial K A-n>-
tems, including the cardiovascular system [2,3]. channels are involved in the response to ischaemia.
The open state probability of K AXP-channels is de- O ther investigators have dem onstra ted  tha t the vas-
pendent on the  cytosolic concentration of ATP. Dur- cular sm ooth muscle cell response to ischaem ia is
ing hypoxia and/or ischaemia, the cytosolic concen­
tra tion  of A T P  falls which directly results in opening 
of K ATP-channels. The subsequent efflux of potassium  
induces hyperpolarization of the cell m em brane 
which shortens the action potential in the  m yocardial
also inhibited by sulphonylurea derivatives, rep re­
sented by a reduction of the post-occlusive hyper- 
aemic response after p re trea tm en t with glibencla­
mide.
Interestingly, the newly developed sulphonylurea
cell leading to  a reduction in the contractile ampli- derivative glimepiride seems to act m ore selectively,
tude of m yocardial cells. In vascular sm ooth muscle since its hypoglycaemic action is m ore pronounced
cells, opening of K ATP-channels and subsequent hy- than that of glibenclamide, w hereas anim al data  sug-
perpolarization  exerts relaxation of these cells, result- gest the absence of in teraction with vascular K
channels [41.
ATI
ing in an  obvious vasodilator response.
The vascular sm ooth muscle cell K AXP-channels 
can be opened  pharmacologically by potassium -chan­
nel-opening drugs such as crom akalim  and the classi- Experimental data in hum ans  
cal vasodilator drug diazoxide [3], G libenclam ide is
able to reduce the vasodilator response to these For several reasons the conclusions from anim al ex- 
K atp channel-opening drugs, indicating the ability periments are not necessarily relevant to the clinical 
to block vascular KATP-channels. A p art from  the situation for trea tm en t of non-insu lin-dependent dia-
__________  betes (N ID D M ) by daily glibenclam ide ingestion:
1 ) the sulphonylurea concentrations used in most ani­
mal studies are much higher than those reached  dur­
ing the treatm ent of N ID D M ; 2 ) in hum an in vivo
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conditions, glibenclamide is highly protein  hound 
which considerably reduces the free drug concentra­
tion; 3) there  are large differences betw een species, 
and therefore the principles of interaction between 
glibenclamide and cardiovascular K ATP-channels are 
not necessarily relevant to the hum an situation; and 
4) the m ajority of the experim ents show an acute in­
teraction betw een sulphonylurea derivatives and car­
diovascular K ATP-channels, but this m ay not be rele­
vant to the  chronic setting of N ID D M  treatm ent.
Up to now, hum an data on this issue are scarce. 
Kosmas et al. [7] recently showed a reduced post-is­
chaemic vasodilation after the oral adm inistration of 
glibenclamide. We recently reported  the effects of 
glibenclamide and tolbutam ide on vascular K ATP- 
channels in hum ans [8-10], In tha t study, the perfused 
forearm technique was used. The in teraction with 
vascular K ATP-channels was studied by investigating 
the in teraction with diazoxide. Therefore, diazoxide 
was used as a pharm acological tool to open vascular 
KATP-channels. In these studies we showed that glib­
enclamide was able to a ttenuate  diazoxide-induced 
and also ischaem ia-induced vasodilation. Since the 
systemic glibenclamide concentrations rem ained 
low, our data were not confounded by m etabolic ef­
fects such as hyperinsulinaem ia or hypoglycaemia. 
Apparently, the perfused forearm  technique with in­
fusions of diazoxide as a K ATP-channel-opener ap­
peared to be an appropriate  hum an in vivo m odel to 
quantify the  K ATP-channel-blocking properties of sul­
phonylurea derivatives at the level of the vascular 
wall. Therefore, we also tested the newly developed 
sulphonylurea derivative glim epiride, tha t has been 
reported to  be devoid of interactions with vascular 
KATP-channels in an animal model. Indeed, when we 
infused glimepiride into the brachial artery, diazoxide 
responses were not inhibited. Apparently, pancreatic 
and vascular K ATP-channels have different character­
istics in humans, which agrees with recent m olecular 
biological observations [8]. Finally, experim ents in 
patients with coronary artery disease have shown 
that ischaemic preconditioning is inhibited 1 h af­
ter the ingestion of 10 mg of glibenclamide [1 1 ]. 
This, as well as the antiarrhythm ic properties of glib­
enclamide in ischaemic conditions, argues for an
interaction between glibenclamide and myocardial 
K ATP-channels.
A lthough the aforem entioned data point towards 
a significant interaction between sulphonylurea de­
rivatives and vascular KATP-channels, the clinical rel­
evance of these observations remains unclear. It is 
obvious that results from clinical trials with well de­
fined end points, like for example the U nited King­
dom Prospective D iabetes Study (UKPDS), are 
needed to  elucidate this interesting issue.
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